ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
Home
Press release
May 17, 2023 07:00 JST
Source:
Northway Biotech
tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
KIEL, GERMANY, May 17, 2023 - (ACN Newswire) - tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
tiakis Biotech AG and Northway Biotech collaboration - tiakis Biotech AG and Northway Biotech:
Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
Andre Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
Source: Northway Biotech
Sectors: BioTech, Healthcare & Pharm
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
TANAKA to Provide Medals for the Tokyo Marathon 2025 That Represent All the Participants in the Event with Woven Lines
Feb 07, 2025 04:00 JST
MHI Thermal Systems to Launch New Model of the "Ene-Conductor" Heat Source Control System
Feb 06, 2025 16:51 JST
Hitachi establishes its fourth Corporate Venture Capital Fund to capture technology turning points and future growth opportunities
Feb 06, 2025 16:32 JST
Approval in Principle (AiP) Acquired from Classification Society for Low-Pressure Type Coastal Liquefied CO2 Carrier
Feb 05, 2025 17:46 JST
Toyota Powers On New North Carolina Automotive Battery Plant
Feb 05, 2025 13:59 JST
Toyota to Form Comprehensive Partnership on Carbon Neutrality with Shanghai and Establish a Company to Develop and Produce BEVs and Batteries
Feb 05, 2025 13:56 JST
Fujitsu to highlight AI-powered network technologies at MWC Barcelona 2025
Feb 05, 2025 10:25 JST
TOYOTA GAZOO Racing Launches Evolved GR Corolla in Japan
Feb 04, 2025 18:41 JST
Mitsubishi Heavy Industries Achieves Double-Digit Order Intake and Profit Growth in First Three Quarters, Raises Full-Year Guidance
Feb 04, 2025 18:34 JST
MAZDA TRANS AOYAMA Opens in Minami-Aoyama
Feb 04, 2025 17:38 JST
Fujitsu launches gen AI software analysis and visualization service to support optimal modernization planning
Feb 04, 2025 11:39 JST
Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies
Feb 03, 2025 17:23 JST
MHI Group Presents "Best Innovation 2024" Awards for Products and Activities that Contribute to Solving Social Issues
Feb 03, 2025 14:31 JST
Fujitsu and Tokai National Higher Education and Research System leverage explainable AI to enhance space weather prediction in collaboration with JAXA
Feb 03, 2025 12:05 JST
Enjoy Anime Tokyo Station in the Metaverse! ANIME TOKYO STATION ON ROBLOX Opens at 3:00 p.m. on January 31, 2025!
Feb 01, 2025 08:00 JST
DENSO Announces Third Quarter Financial Results
Jan 31, 2025 18:09 JST
Rally Driver Hiroshi Masuoka Receives the Person of Sports Merit Award in Japan
Jan 31, 2025 15:12 JST
TANAKA PRECIOUS METAL TECHNOLOGIES Launches Visi Fine(R): A Group of Precious Metal Materials for Medical Device Components
Jan 31, 2025 11:00 JST
Mazda Production and Sales Results for December 2024 and for January through December 2024
Jan 30, 2025 16:44 JST
Lexus Announces Global Sales Results for 2024
Jan 30, 2025 15:52 JST
More Latest Release >>
Related Release
Mallia Therapeutics and Northway Biotech Announce Partnership for the Manufacturing of Soluble CD83 Protein for Hair Loss Treatment
February 04 2025 18:00 JST
iTolerance, Inc. and Northway Biotech Announce Partnership Agreement for Manufacturing of Streptavidin-FasL Fusion Protein for Innovative iTOL-100 Immunomodulatory Technology
August 01 2023 20:00 JST
Northway Biotech Set to Launch Advanced Microbial and Mammalian GMP Facilities in Massachusetts
May 25 2023 00:20 JST
More Press release >>